All AbMole products are for research use only, cannot be used for human consumption.
Firocoxib is a coxib exhibiting high selectivity to inhibit COX-2. In vitro canine whole blood assays have demonstrated Firocoxib to be 350–430-fold more selective for COX-2 than for COX-1. COX-1 is constitutively expressed and enzymatically active in a variety of sites, including the stomach, intestine, kidneys, and platelets. COX-1 is the isoform largely responsible for the physiologic functions of eicosanoids, including gastric mucosal protection, renal blood flow, and vascular hemostasis. COX-2 expression is primarily induced by mediators such as serum growth factors, cytokines, and mitogens. COX-2 is primarily responsible for the synthesis of eicosanoids associated with inflammation.
| Cell Experiment | |
|---|---|
| Cell lines | isolated peripheral blood mononuclear cells |
| Preparation method | Peripheral blood mononuclear cells were isolated by density gradient centrifugation and incubated at 37°C with medium alone, firocoxib (100 ng/mL), LPS (1 ng/mL or 1 μg/mL), or combinations of firocoxib and both LPS concentrations. After 4 hours, supernatants were collected and tested for prostaglandin E2 (PGE2) concentration with an enzyme inhibition assay, and gene expression in cell lysates was measured with PCR assays. |
| Concentrations | 100 ng/mL |
| Incubation time | 4h |
| Animal Experiment | |
|---|---|
| Animal models | Mouse Model of Incisional Pain by objective measurement of mechanical allodynia and thermal hyperalgesia using von Frey and Hargreaves equipment |
| Formulation | diluted in sterile 0.9% physiologic saline |
| Dosages | 10 or 20 mg/kg |
| Administration | intraperitoneally |
| Molecular Weight | 336.4 |
| Formula | C17H20O5S |
| CAS Number | 189954-96-9 |
| Solubility (25°C) | DMSO ≥ 45 mg/mL |
| Storage | -20°C, protect from light, sealed |
[1] Sarah A Wagner, et al. Pharmacokinetics of oral firocoxib in un-weaned calves
[2] Josh R Donnell, et al. Use of firocoxib for the treatment of equine osteoarthritis
[3] Bachir Latli, et al. Synthesis of stable isotope-labelled firocoxib
| Related COX Products |
|---|
| Celecoxib
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). |
| Nepafenac
Nepafenac is an analgesic selective inhibitor of COX-2. |
| Ampiroxicam
Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory compound. |
| Bromfenac Sodium
Bromfenac is a nonsteroidal anti-inflammatory compound (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. |
| Bufexamac
Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
